Cipla receives final approval for generic version of GlaxoSmithKline's IMITREX®

Cipla Limited (BSE: 500087; NSE: CIPLA EQ hereinafter referred to as "Cipla") today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Sumatriptan Nasal Spray, 20 mg from the United States Food and Drug Administration (U.S. FDA).

Cipla's Sumatriptan Nasal Spray USP, 20 mg is an AB-rated generic therapeutic equivalent version of GlaxoSmithKline's Imitrex® Nasal Spray.

Imitrex® Nasal Spray is a serotonin (5-HT1B/1D) receptor agonist (triptan) indicated for acute treatment of migraine with or without aura in adults.

According to IQVIA (IMS Health), Imitrex® Nasal Spray 20mg and its generic equivalents had US sales of approximately $53.3M for the 12-month period ending December 2020.

Shares of CIPLA LTD. was last trading in BSE at Rs.789.5 as compared to the previous close of Rs. 786.55. The total number of shares traded during the day was 117960 in over 2992 trades.

The stock hit an intraday high of Rs. 807.7 and intraday low of 782.05. The net turnover during the day was Rs. 93348550.

Source : Equity Bulls

Keywords